

<b>Examiner-Initiated Interview Summary</b>	<b>Application No.</b> 09/819,249	<b>Applicant(s)</b> WALDMAN ET AL.	
	<b>Examiner</b> Alexander H. Spiegler	<b>Art Unit</b> 1637	

  

**All Participants:**

(1) Alexander H. Spiegler.

(2) Paul Carango.

**Date of Interview:** 5 February 2004

**Type of Interview:**

☒ Telephonic

☐ Video Conference

☐ Personal (Copy given to: ☐ Applicant    ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes    ☐ No

If Yes, provide a brief description: \_\_\_\_\_

**Part I.**

Rejection(s) discussed:

*None*

Claims discussed:

*1, 11, 21 and 29*

Prior art documents discussed:

*None*

**Part II.**

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

*See Continuation Sheet*

**Part III.**

☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.

☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

**Status of Application:** \_\_\_\_\_

(3) \_\_\_\_\_

(4) \_\_\_\_\_

**Time:** \_\_\_\_\_

  

(Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed:

Applicant's attorney, Paul Carango authorized the following proposed Examiner's Amendment:

In Claim 1, after "wherein", delete "said guanylin cyclase C...in said sample", and insert -- expression of guanylin cyclase C indicates the presence of primary and/or metastatic esophageal cancer cells in said sample --.

In Claim 11, delete, "evidence of".

In Claim 11, after "wherein", delete "guanylin cyclase C...cancer cells", and insert -- the presence of guanylin cyclase C gene transcription and translation products indicate the presence of primary and/or metastatic esophageal cancer cells in said sample --

In Claim 21, after "whether", delete "a", and insert -- said --.

In Claim 29, delete "an esophageal sample", and insert -- said sample --.

Cancel Claims 41 and 42

The title has been changed to "Methods of Screening and Diagnosing Esophageal Cancer by Determining Guanylin Cyclase C Expression"..